ERBB2 and colorectal carcinoma: A prior study reported HER2 amplification in 18.4% (16 of 87) of CRC cases with brain metastases, demonstrating a significantly higher risk compared to HER2-negative CRC cases, with accounted to 75% concordance rate in HER2 status between primary CRC tumors and paired brain metastases sample (16, 17).